An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer

Li, N; Bu, HL; Liu, JH; Zhu, JQ; Zhou, Q; Wang, L; Yin, RT; Wu, XH; Yao, SZ; Gu, KS; Zhang, H; Li, GL; Pan, HM; Wu, Q; An, RF; Yang, XF; Zhu, YP; Wan, XP; Duan, W; Xiong, JP; Guo, HY; Lou, G; Wang, J; Hu, WJ; Zhang, X; Meng, YG; Zhang, B; Wang, YT; Wang, QR; Wu, LY

Wu, LY (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Dept Gynecol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China.

CLINICAL CANCER RESEARCH, 2021; 27 (9): 2452

Abstract

Purpose: Fluzoparib (PARP inhibitor) showed promising antitumor activity for advanced ovarian cancer in a phase I study. This study aimed to assess th......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索